Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095732 · ClinicalTrials.gov registry record · Phase 2
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT00095732 is a Phase 2 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 129 participants.
The verdict
NCT00095732, a Phase 2 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency.
Interventions
- DRUG Placebo
- DRUG Liprotamase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095732
The ClinicalTrials.gov registry entry for NCT00095732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00095732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095732 about?
NCT00095732 is a clinical study titled "Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency". The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency.
What is the current status of trial NCT00095732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2004-06. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00095732?
The interventions under investigation include: Placebo (DRUG), Liprotamase (DRUG).
Who is sponsoring clinical trial NCT00095732?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.